



SUPPLEMENTARY MATERIAL

Supplementary Figure S1: TEE periprocedural protocol



Typical periprocedural TEE (transesophageal echocardiography) views during T-TEER, grouped according to the 4 right-sided chamber views. TV: tricuspid valve, RV: right ventricle, RA: right atrium, A: anterior leaflet, P: posterior leaflet, S: septal leaflet, AV: aortic valve, PV: pulmonary valve, LV: left ventricle, *clip delivery system

Supplementary Figure S2: TTE follow-up



Follow-up investigation after T-TEER, based on the concept of the 4 right-sided chamber views in a patient with reduction from torrential to severe TR. A: anterior leaflet, P: posterior leaflet, S: septal leaflet, RV: right ventricle, RA: right atrium, IVC: inferior vena cava, SVC: superior vena cava, AV: aortic valve, PV: pulmonary valve, LV: left ventricle, LA: left atrium, *2xTriClip™, *MitraClip™.


Supplementary Figure S3. Procedural steps of multimodality imaging guidance

| Steps | Fluoroscopy Only | Chamber views (fluoroscopy + TTE) | | | | TEE |
|--------------------------------------|------------------|-----------------------------------|-----------|-----------|-----------|--------|
| | | 1-chamber | 2-chamber | 3-chamber | 4-chamber | |
| 1. Venous access* | ██████ | | | | | |
| 2. SGC advancement to RA | ██████ | | | | | |
| 3. Clip straddle and steering down | | | ██████ | ██ | ██████ | |
| 4. Clip positioning and clocking | | ██████ | ██ | ██ | | |
| 5. Clip advancement to RV | | | ██████ | ██ | | |
| 6. Grasping and leaflet insertion | | | ██████ | | | ██ |
| 7. Verification of leaflet insertion | | | ██████ | | | ██████ |

 → mandatory
  → helpful
  → optional

TTE: transthoracic echocardiography; TEE: transesophageal echocardiography; 1- to 4-chamber annotations refer to the 4 right-sided chamber views explained in the imaging and procedural protocols; SGC: steerable guide catheter; RA: right atrium; RV: right ventricle; * ultrasound-guided puncture.

Supplementary Figure S4. TR reduction to baseline



Comparison of regurgitation reduction between the multimodality (MMI) and transesophageal echocardiography (TEE) groups, according to the 5-grade classification (I/V° to V/V°) for tricuspid regurgitation (TR).

Supplementary Table S1: TEE periprocedural protocol

| TEE View | | Focus | |
|----------------------|---|--|---|
| | | Morphology | Guiding |
| Bicaval view | | TV position related to caval veins | Orientation SGC towards TV |
| Transgastric views | Short axis (RH 1 chamber view) | "en face" TV view | Selecting clip target |
| | Long axis (RH 2 chamber view) | RV inflow | Clip orientation / perpendicularity to TR jet |
| Mid-esophageal views | 0° (RH 4 chamber view) | SL length, tethering, restriction | SL grasping |
| | 40-90° (RH 3 chamber view) | SL visualization AL vs PL distinction Leaflet length, tethering, restriction | Grasping all leaflets Coaptation gap |
| | 90-130° | SL visualization AL vs PL distinction Leaflet length, tethering, restriction | Grasping all leaflets Coaptation gap |
| 3D-views | | Leaflets and commissures CIED leads | Clip orientation |

TEE: transesophageal echocardiography, RH: right heart, TV: tricuspid valve, RV: right ventricle, SGC: steering guide catheter, AL: anterior leaflet, PL: posterior leaflet, SL: septal leaflet

Supplementary Table S2. Baseline characteristics (extended)

| Characteristic | | MMI (n=17) | TEE (n=23) | p-value | Characteristic | MMI (n=17) | TEE (n=23) | p-value |
|--------------------------|-----------|---------------|---------------|------------------|-----------------------------|---------------|---------------|---------|
| Clinical | | | | | Comorbidities | | | |
| Age (years) | | 83.1±4.1 | 81±5.3 | 0.182 | Atrial fibrillation | 16 (94%) | 23 (100%) | 1.000 |
| Female sex | | 10 (59%) | 10 (44%) | 0.595 | Pulmonary hypertension | 16 (94%) | 22 (96%) | 1.000 |
| TTE acoustic window | Excellent | 17 (100%) | 0 (0%) | <0.001 | Type 2 diabetes | 6 (35%) | 10 (43%) | 0.773 |
| | Good | 0 (0%) | 2 (9%) | 0.506 | Arterial hypertension | 17 (100%) | 23 (100%) | 1.000 |
| | Moderate | 0 (0%) | 13 (57%) | 0.004 | Hyperlipoproteinemia | 6 (35%) | 15 (65%) | 0.405 |
| | Poor | 0 (0%) | 8 (34%) | 0.037 | Tobacco | 2 (12%) | 2 (9%) | 1.000 |
| BMI (kg/m ²) | | 22.9±1.1 | 30.4±3.7 | <0.001 | COPD | 3 (18%) | 6 (26%) | 0.719 |
| EuroSCORE II (%) | | 10.1±8.2 | 8.6±5.6 | 0.496 | CKD stage 3-5 | 14 (82%) | 19 (83%) | 1.000 |
| Frailty (indices) | | 2.5±0.9 | 2.2±1.1 | 0.890 | Prior stroke / TIA | 3 (18%) | 5 (22%) | 1.000 |
| STS Score MVR (%) | | 11.1±7.4 | 10.6±5.9 | 0.813 | Coronary artery disease | 8 (47%) | 15 (65%) | 0.339 |
| STS Score MVR (%) | | 8.7±7.7 | 7.8±5.8 | 0.675 | Coronary bypass graft | 1 (6%) | 2 (9%) | 1.000 |
| Major organ compromise | | 2.5±1.4 | 2.3±1.1 | 0.616 | Prior myocardial infarction | 1 (6%) | 5 (22%) | 0.380 |
| NYHA class III-IV | | 15 (88%) | 20 (87%) | 1.000 | Peripheral artery disease | 4 (23%) | 7 (30%) | 1.000 |
| RHF hospitalizations | | 2.8±0.7 | 2.5±0.7 | 0.188 | Pacemaker / ICD / CRT | 5 (29%) | 4 (17%) | 0.712 |
| KCCQ Score | | 32.3±18.7 | 26.7±14.7 | 0.295 | Prior MV repair | 7 (41%) | 3 (13%) | 0.164 |
| 6-minute walk test | | 183.2±91.3 | 162.1±94.1 | 0.482 | | 1 (10%) | 1 (4%) | 1.000 |

Data presented as n (%) or mean ± SD. BMI : body mass index ; EuroSCORE: European System for Cardiac Operative Risk Evaluation Score; STS: Society of Thoracic Surgeons predicted risk of mortality -> calculated based on either isolated mitral valve replacement (MVR) or mitral valve repair (MVR); NYHA: New York Heart Association; RHF: right heart failure; KCCQ: Kansas City Cardiomyopathy Questionnaire; COPD: chronic obstructive pulmonary disease; CKD: chronic kidney disease; TIA: transient ischemic attack; ICD: implantable cardioverter defibrillator; CRT: cardiac resynchronization therapy; MV : mitral valve

Supplementary Table S3. Echocardiographic parameters

| Variable | TTE | | | TEE | | | TTE vs TEE (Δ) |
|--|--------------------|---------------------|---------|--------------------|---------------------|---------|-------------------------|
| | Baseline (n=17) | 12 months (n=15) | p-value | Baseline (n=23) | 12 months (n=19) | p-value | p-value |
| TR parameters | | | | | | | |
| PISA EROA (mm ²) | 82.1±34.5 | 33.7±35.7 | <0.001 | 77.5±36 | 23.8±20.1 | <0.001 | 0.764 |
| Mean vena contracta (mm) | 16.2±4.8 | 7.8±5.5 | <0.001 | 16.8±4.3 | 6.2±3.2 | <0.001 | 0.542 |
| TR volume (mL/beat) | 70.4±22.7 | 31.8±34.4 | <0.001 | 84.2±36.5 | 24.2±19.8 | <0.001 | 0.112 |
| PISA (mm) | 9.1±1.7 | 5.9±4.3 | 0.006 | 9.5±2.3 | 5.3±2.8 | <0.001 | 0.940 |
| Jet area (4ch) (cm ²) | 18.8±6.7 | 10.8±9.4 | <0.001 | 17.3±7.5 | 7.8±4.7 | <0.001 | 0.517 |
| IVC diameter (mm) | 24.1±7.7 | 15.7±7.5 | <0.001 | 23.9±5.8 | 17.7±6.6 | <0.001 | 0.639 |
| Hepatic vein flow reversal (%) | 13 (77%) | 4 (27%) | 0.120 | 19 (83%) | 1 (5%) | 0.001 | 0.212 |
| Tenting height (mm) | 8.5±1.8 | -- | -- | 8.5±1.9 | -- | -- | 0.492 |
| Coaptation gap | 7.7±2.7 | -- | -- | 8.1±2.4 | -- | -- | 0.325 |
| Right heart remodeling | | | | | | | |
| RA indexed volume (mL/m ²) | 99.3±61.9 | 58.4±39.9 | <0.001 | 86.1±33.7 | 39.1±30.4 | <0.001 | 0.882 |
| Base RVEDD (4ch) (mm) | 52.1±9.1 | 48.9±9.3 | 0.001 | 55.5±6.8 | 49.6±7.4 | <0.001 | 0.464 |
| TV annular diameter (mm) | 44.1±7.7 | 41.1±8.7 | <0.001 | 46.1±6.5 | 41.6±7.1 | <0.001 | 0.101 |
| Ventricular systolic function | | | | | | | |

| | | | | | | | |
|-------------------------------|------------|------------|--------|------------|------------|--------|-------|
| RV TAPSE (mm) | 16.1±4.1 | 20.6±5.2 | <0.001 | 15.7±3.8 | 19.3±3.4 | <0.001 | 0.702 |
| RV FAC (%) | 33.5±7.2 | 41.8±10 | 0.023 | 29.5±8.7 | 33.3±15.3 | 0.029 | 0.469 |
| Annular velocity TDI (cm/s) | 9.2±3.2 | 13.7±4.3 | 0.023 | 8.7±1.9 | 17.3±11.4 | 0.002 | 0.729 |
| LV ejection fraction (%) | 51.5±12.4 | 52.6±8.9 | 0.095 | 53.9±12.9 | 54.1±9.9 | 0.054 | 0.628 |
| Hemodynamic parameters | | | | | | | |
| TR peak velocity (cm/s) | 311.9±46.9 | 282.3±33.7 | 0.008 | 331.2±40.1 | 287.6±54.2 | <0.001 | 0.692 |
| PAPs | 58±11.7 | 48.3±7.3 | 0.015 | 62.8±10.6 | 48.4±14.8 | <0.001 | 0.718 |
| LV stroke volume (mL) | 54.8±10.6 | 60.1±9.7 | <0.001 | 54.2±8.8 | 56.7±10 | 0.300 | 0.410 |
| Cardiac output (L/min) | 3.9±0.9 | 4.4±0.7 | 0.002 | 3.8±0.9 | 3.9±0.7 | 0.501 | 0.108 |
| RV stroke volume (mL) | 60.5±10.9 | 65.4±10.4 | 0.001 | 59.1±10.8 | 62.2±11.2 | 0.013 | 0.261 |

Data presented as n (%) or mean ± SD. PISA EROA: proximal isovelocity surface area effective regurgitant orifice area; TR: tricuspid regurgitation; ch: chamber; IVC : inferior vena cava ; RA: right atrium; RVEDD: right ventricular end-diastolic diameter; TV: tricuspid valve; TAPSE: tricuspid annular plane systolic excursion; FAC: fractional area change; TDI: tissue doppler imaging; LV: left ventricle; PAPs: pulmonary systolic artery pressure

VIDEO LEGENDS

Video S1. One-chamber TTE view

Video illustration of the 1-chamber right heart view in a patient with massive tricuspid regurgitation (Figure 1), containing the 2D subcostal short axis and the 3D “en face” tricuspid valve visualization derived from subcostal, apical or parasternal views.

Video S2. TTE screening for the 4 right-sided chamber views

Video compilation matching Figure 1 (Main text)

Video S3. Procedural steps of MMI guided T-TEER

Video sequence matching Figure 4 (Main text)